Abstract Background & Aims The aim of this integrated analysis was to assess the efficacy of
the once‐daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without …

Background Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV).
We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 …

People with hepatitis C virus (HCV) infection other than genotype 1 represent a
heterogeneous group. The aim of the phase 2 C‐SCAPE study was to evaluate …

Background & Aims Patients infected with hepatitis C virus (HCV) genotype 1, 4, or 6, with or
without cirrhosis, previously treated with peg-interferon and ribavirin, are a challenge to …

Abstract Background & Aims Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent
in sub‐Saharan Africa and the Middle East, particularly in Egypt. This study evaluated the …

Summary Elbasvir (EBR; HCV NS 5A inhibitor) and grazoprevir (GZR; HCV NS 3/4A
protease inhibitor) are approved as a fixed‐dose combination to treat patients chronically …

Abstract Background and Aim Although treatment with direct‐acting antivirals has
dramatically improved morbidity and mortality attributable to chronic hepatitis C virus …

Background & Aims Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease
inhibitor) are direct-acting antiviral agents recently approved in the United States for …

The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study
assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV …

Aim The present study aimed to determine the real‐world efficacy and safety of the non‐
structural protein (NS) 5A inhibitor elbasvir (EBR) combined with the NS3/4A protease …